Dabrafenib a new melanoma drug in metastatic melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA. The BREAK-3 study compared treatment with dabrafenib with that of standard dacarbazine chemotherapy for patients with previously untreated, advanced melanoma